AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for KN motif and ankyrin repeat domain-containing protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q63ZY3

UPID:

KANK2_HUMAN

Alternative names:

Ankyrin repeat domain-containing protein 25; Matrix-remodeling-associated protein 3; SRC-1-interacting protein

Alternative UPACC:

Q63ZY3; B0I1P4; Q3KQZ3; Q6GUF5; Q9H8S4; Q9NUP0; Q9P210

Background:

KN motif and ankyrin repeat domain-containing protein 2, also known as Ankyrin repeat domain-containing protein 25, Matrix-remodeling-associated protein 3, and SRC-1-interacting protein, plays a pivotal role in various cellular processes. It is involved in transcription regulation, apoptosis, vitamin D receptor signaling, actin stress fibers formation, and cell adhesion and migration. Its interaction with ARHGDIA and influence on the Rho signaling pathway are crucial for podocyte migration and cell proliferation.

Therapeutic significance:

This protein's involvement in Palmoplantar keratoderma and woolly hair, and Nephrotic syndrome 16, underscores its potential as a target for therapeutic intervention. Understanding the role of KN motif and ankyrin repeat domain-containing protein 2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.